Prelude announces multiple clinical and preclinical poster presentations at aacr-nci-eortc international conference

Wilmington, del. and boston, oct. 14, 2023 (globe newswire) -- prelude therapeutics incorporated (“prelude”) (nasdaq: prld), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics, known as the triple meeting, from october 11 - 15, 2023 at the hynes convesntion center in boston, ma. the four prelude poster presentations include data from two ongoing phase 1 clinical trials for prelude's cdk9 inhibitor, prt2527, and cdk4/6 inhibitor, prt3645, and two preclinical posters for our smarca2 degrader compound, prt3789.
PRLD Ratings Summary
PRLD Quant Ranking